Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.52 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.52 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.52 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.52 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | TACR2 | P21452 | 3/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.47 |
| ▸ | CDC25B | P30305 | 6/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.45 |
| ▸ | GJB2 | P29033 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13129807 | 1.00 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL20121760 | 1.00 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL18482785 | 1.00 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL24378346 | 1.00 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13129786 | 1.00 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL25480956 | 1.00 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13130066 | 1.00 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL24378351 | 1.00 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL21172812 | 1.00 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL18649254 | 1.00 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236935-B2 | Gem-difluorinated C-glycoside compounds derived from podophyllotoxin, their preparation and their applications | INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (INSA) (FR) | 2012-08-07 | — | — | US | disclosed |
| US-8088904-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-7816328-B2 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100004160-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | RYBCZYNSKI PHILIP | 2010-01-07 | — | — | US | disclosed |
| US-20090318678-A1 | Stable C-Glycoside Sugar and C-Glycoconjugate Mimetics, Method for preparing same and uses Thereof in Particular in Cosmetics and Drugs | TFCHEM (FR) | 2009-12-24 | — | — | US | disclosed |
| US-20090318675-A1 | NOVEL GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS DERIVED FROM PODOPHYLLOTOXIN, THEIR PREPARATION AND THEIR APPLICATIONS | SUNSHINE BIOPHARMA INC. (CA) | 2009-12-24 | — | — | US | disclosed |
| US-20090105162-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | RYBCZYNSKI PHILIP | 2009-04-23 | — | — | US | disclosed |
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| US-7482330-B2 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004160-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | UGCG, UGGT1, GCG | SSTR1 3346/4885SSTR2 2990/4885SSTR4 2880/4885 |
| US-20090318675-A1 | NOVEL GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS DERIVED FROM PODOPHYLLOTOXIN, THEIR PREPARATION AND THEIR APPLICATIONS | GLRA3, GMNN, B3GAT3 | SSTR1 2007/4885SSTR2 2494/4885SSTR4 2156/4885 |
| US-20090318678-A1 | Stable C-Glycoside Sugar and C-Glycoconjugate Mimetics, Method for preparing same and uses Thereof in Particular in Cosmetics and Drugs | CA7, GPR119, SLC5A2 | SSTR1 82/4885SSTR2 72/4885SSTR4 161/4885 |
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | HNRNPM, POLM, RNMT | SSTR1 4835/4885SSTR2 4794/4885SSTR4 4819/4885 |
| US-20090105162-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | UGCG, UGGT1, GCG | SSTR1 3346/4885SSTR2 2990/4885SSTR4 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.